Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kristy Schweighardt

Physician Assistant Orange Park, FL Physician Assistant

NPI 1497230585 CMS profile 10538015

1893 Kingsley Ave, Suite B, Orange Park, FL 32073

Open in the dashboard

General payments

$14,540

627 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristy Schweighardt of Orange Park, FL is reported in the CMS Open Payments database as having received $14,540 across 627 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,316 170
2024 General $3,834 177
2023 General $2,482 108
2022 General $2,591 108
2021 General $1,317 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristy Schweighardt
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kristy Schweighardt were reported at $4,316. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kristy Schweighardt Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,317 $132 $37–$438 $132
2022 $2,591 $155 $48–$522 $149
2023 $2,482 $167 $52–$557 $160
2024 $3,834 $178 $55–$600 $164
2025 $4,316 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,236 99 payments
  2. Genzyme Corporation $1,966 58 payments
  3. Arcutis Biotherapeutics, Inc. $1,506 17 payments
  4. Janssen Biotech, Inc. $1,282 69 payments
  5. Sun Pharmaceutical Industries Inc. $1,010 35 payments
  6. LEO Pharma Inc. $818 48 payments
  7. Novartis Pharmaceuticals Corporation $814 61 payments
  8. E.R. Squibb & Sons, L.L.C. $744 29 payments
  9. Regeneron Healthcare Solutions, Inc. $652 31 payments
  10. Dermavant Sciences, Inc. $643 38 payments
  11. Other $2,870 142 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,997 619 payments
  2. Consulting Fee $1,000 1 payment
  3. Education $543 7 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT $2,809 82 payments
  2. RINVOQ $1,472 47 payments
  3. Zoryve $1,437 16 payments
  4. TREMFYA $1,198 55 payments
  5. SOTYKTU $744 29 payments
  6. VTAMA $742 52 payments
  7. ADBRY $673 37 payments
  8. Otezla $579 26 payments
  9. SKYRIZI $498 27 payments
  10. Winlevi $466 15 payments
  11. Other $5,139 301 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

752

Median for Physician Assistant: 241

Drug cost

$691,898

Median for Physician Assistant: $4,110

Branded share of claims

16.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 91 $420,257
Cosentyx Unoready Pen Secukinumab Brand 16 $194,886
Dupixent Syringe Dupilumab Brand 15 $55,340
Clobetasol Propionate Generic 166 $7,479
Azelaic Acid Generic 16 $2,427
Fluorouracil Generic 32 $2,308
Tacrolimus Generic 23 $1,797
Ketoconazole Generic 93 $1,719
Metronidazole Generic 18 $1,209
Calcipotriene Generic 12 $1,098

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$100,662

Medicare's payments for the services billed

Medicare patients

630

Average age 74

Services billed

2,690

373 women, 257 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 30%
Ischemic heart disease 30%
Chronic kidney disease 23%
Depression 20%
Atrial fibrillation 19%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $473
  • Regeneron Healthcare Solutions, Inc. $220
$693 106 —
TREMFYA
  • Janssen Biotech, Inc. $394
$394 — —
VTAMA
  • Dermavant Sciences, Inc. $356
$356 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $339
$339 — —
RINVOQ
  • AbbVie, Inc. $331
$331 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

627 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record